Astellas Pharma's Profit Surges 475% in Fiscal 2025

-- Astellas Pharma's (TYO:4503) profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.

The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.

Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.

During the year, Astellas Pharma booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.

The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.

For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.

Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than the amount paid in the year-ago period.

罗斯柴尔德公司（Rothschild & Co Redburn）将奥的斯全球（Otis Worldwide）的目标股价从112美元下调至101美元，维持“买入”评级。

根据FactSet调查的分析师报告，奥的斯全球（OTIS）的平均评级为“增持”，平均目标价为93.54美元。（报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）Price: $78.45, Change: $+0.50, Percent Change: +0.64%

$OTIS

NICE表示，贝尔集成公司选择CXone平台来支持服务台项目。

NICE（NICE）周一宣布，信息技术服务和咨询公司Bell Integration已选择其CXone平台为其服务台和业务拓展运营提供支持。该公司表示，初期部署将在三个地点进行，最多可支持1000名员工。财务细节未予披露。 NICE股价在早盘交易中上涨近2%。Price: $102.69, Change: $+2.34, Percent Change: +2.33%

$NICE

美国银行证券将西部数据的目标股价从415美元下调至495美元。

根据FactSet调查的分析师报告，西部数据（WDC）的平均评级为“增持”，平均目标价为387.27美元。（报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）Price: $402.91, Change: $-1.09, Percent Change: -0.27%

$WDC

相关文章

罗斯柴尔德公司（Rothschild & Co Redburn）将奥的斯全球（Otis Worldwide）的目标股价从112美元下调至101美元，维持“买入”评级。

NICE表示，贝尔集成公司选择CXone平台来支持服务台项目。

美国银行证券将西部数据的目标股价从415美元下调至495美元。